Merus (MRUS)
(Delayed Data from NSDQ)
$43.91 USD
-1.11 (-2.47%)
Updated May 17, 2024 04:00 PM ET
After-Market: $44.00 +0.09 (0.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Merus N.V. [MRUS]
Reports for Purchase
Showing records 121 - 140 ( 173 total )
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
CD137 Bispecific Antibody Kills Tumors in Mice
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
NRG1 Fusion Focus for MCLA-128 Ultimately a Positive
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Refocusing Efforts in NRG1 Fusion - Positive Solid Tumors
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
SITC Is Only 33 Days Away: Abstract Titles Released
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Biotechnology - ESMO 2019 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Elevating the Game with Multiple Escalation Studies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
2Q19 - T-Cell Engager Shows Early Signs of Activity
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Initiating at Buy with $20 PT.
Provider: Roth Capital Partners, Inc.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
1Q19 Financials; Multiple Updates Coming in H2
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Biotechnology - AACR Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
4Q18 Financials; Early-Stage Biclonics Programs Hold Significant Promise
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
3Q18 Financials; Data-Rich 2H19 Expected for MCLA-128, 117 and 145
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D